11α-Hydroxyprogesterone, a Potent 11β-Hydroxysteroid Dehydrogenase Inhibitor, Is Metabolized by Steroid-5α-Reductase and Cytochrome P450 17α-Hydroxylase/17,20-Lyase to Produce C11α-Derivatives of 21-Deoxycortisol and 11-Hydroxyandrostenedione In Vitro

The document reports a study on the metabolism of 11α-hydroxyprogesterone (11αOHP4), a potent inhibitor of 11β-hydroxysteroid dehydrogenase (11βHSD) type 2, and its conversion to various metabolites by steroid-5α-reductase (SRD5A) and cytochrome P450 17α-hydroxylase/17,20-lyase (CYP17A1). The study found that 11αOHP4 is not a substrate for 11βHSD2 but is metabolized by SRD5A and CYP17A1 to produce 11α-hydroxydihydroprogesterone, 11α,17α-dihydroxyprogesterone, and 11α-hydroxyandrostenedione. Additionally, the presence of 11αOHP4 and its metabolites was detected in prostate cancer tissue, suggesting a potential role in human pathophysiology. The study highlights the need for further research to understand the impact of 11αOHP4 and its metabolites. The number of participants or specific sample sizes for the experiments were not provided in the summary.